Strengthening rebate regulations... What is the pharmaceutical company’s response strategy?

Daeryun Law Firm holds a seminar on compliance issues in the pharmaceutical sector

As the importance of legal and practical response is increasing due to the strengthening of rebate-related regulations, issues and practical points that pharmaceutical companies and promotional sales operators (CSOs) should pay attention to, focusing on the revision of the Pharmaceutical Affairs Act, were introduced.

On the 7th, Daeryun Law Firm (Lihan) held a seminar with the theme of 'Issues and practices of compliance in the pharmaceutical field: Focusing on the revision of the Pharmaceutical Affairs Act.'

This seminar, which was held for pharmaceutical companies and CSO personnel in the conference room of Daeryun headquarters in Yeouido, was held in four sessions, including △ expenditure report preparation and disclosure system for pharmaceutical companies and CSOs △ pharmaceutical industry rebate regulation and CP △ pharmaceutical rebate regulation practice △ response to rebate and tax issues.

In the session 'Pharmaceutical companies and CSOs' expenditure report preparation and disclosure system (Attorney Choi Yoon-jeong)', the CSO reporting system, expenditure report preparation methods, and practical issues will be discussed, focusing on the revised Pharmaceutical Affairs Act.

In the second session, 'Pharmaceutical Industry Rebate Regulations and CP (Attorney Gye-Jun Son)', regulations on pharmaceutical rebates under the Fair Trade Act, analysis of Fair Trade Commission sanctions cases, and CP construction strategies for each pharmaceutical company are presented.

In the third session, 'Pharmaceutical rebate regulation practice (Adviser Choi Myeong-soon)', HIRA's follow-up management of supply details related to pharmaceutical distribution and analysis of expenditure reports and administrative disposition cases of pharmaceuticals that disrupt distribution order will be conducted. In the fourth session, 'Response to rebates and tax issues (Tax accountant Jeong-oh Lim)', tax investigation and taxation flows and response plans related to rebate pharmaceutical companies will be shared.

In his opening speech, CEO Kim Kook-il said, “At a time when rebate-related regulations are being strengthened, such as the expansion of CSOs to those subject to expenditure report submission, CSO reporting system, expenditure report preparation, and disclosure system, the importance of legal and practical response is gradually increasing.” He added, “I hope that today’s event will be an opportunity to discuss the latest regulations related to pharmaceutical companies and CSO rebates and response strategies from practitioners’ perspectives from various angles.”

Meanwhile, the seminar will be held simultaneously in the conference room (offline) and webinar (online) at Daeryun Law Firm's headquarters.

Reporter Kim Hong-jin (khj@kpanews.co.kr)

[View full article]
Pharmacy public opinion - Strengthening rebate regulations... What is the pharmaceutical company’s response strategy? (Shortcut)
Medipana News - "CSO/expenditure report, there are contradictory regulations... Target and scope need to be specified" (Shortcut)
Pharmacist Public Theory - Application for 2025 CP rating evaluation begins... What are the changes and additions to keep in mind? (Shortcut)